Adult Disease Clinical Trial
Official title:
A Comparison of Pain Severity on Injection of MCT/LCT Propofol Between Lidocaine 20 mg, 40 mg, and Without Lidocaine.
To compare the severity of pain on injection of MCT/LCT propofol with lidocaine 20 mg, 40 mg, and without lidocaine.
Background: Intravenous injection of propofol produces pain. Many factors are involved and
various techniques have been tried to minimize the propofol-induce pain with variable
results.
Objective: To compare the severity of pain on injection of MCT/LCT propofol with lidocaine
20 mg, 40 mg, and without lidocaine.
Design: Randomize controlled trial. Method: Two hundred and ten ASA class I - III patients
undergoing elective surgery were blinded and equally allocated into 3 groups. Patients in
group N, L1, and L2 received MCT/LCT propofol 10 ml mixed with 0.9% NaCl 2 ml, 1% lidocaine
2 ml, and 2% lidocaine 2 ml respectively. Pain at time of propofol injection was assessed by
blinded anesthesiologist on a four point scale ; 0 = no pain, 1 = mild pain, 2 = moderate
pain, and 3 = severe pain. Results: Patient's demographic data of each group were similar.
There were significant differences in the incidence of propofol injection without pain among
groups (p<0.001). The numbers of patients who had moderate and severe pain in groups L1 and
L2 were significantly less than those in group N (p<0.001). The mean blood pressure and
heart rate were not significant differences in among groups. Conclusion : The amount of 20
mg, and 40 mg lidocaine to MCT/LCT propofol in our study is equally effective in decreasing
pain and more effective than MCT/LCT propofol alone group significantly. They were no
significant differences in hemodynamics change in among groups.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Completed |
NCT02309164 -
The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).
|
N/A | |
Unknown status |
NCT01614353 -
Medication-taking Preferences & Practices of Patients With Chronic Conditions
|
N/A | |
Recruiting |
NCT05817734 -
Human Phenotype Project Study Protocol
|
||
Recruiting |
NCT06403436 -
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04291417 -
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Baylor S&W
|
||
Recruiting |
NCT04643015 -
New Ways of Doing Magnetic Resonance Imaging in Children and Adults
|
||
Active, not recruiting |
NCT03986879 -
Relationship of the Physical Activity Practice and Its Different Domains With Cardiac Autonomic Modulation
|
||
Completed |
NCT03119220 -
Applying a Stress Framework to Health Behavior Change: A Fitbit Study
|
N/A | |
Recruiting |
NCT04855929 -
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.
|
Phase 1 | |
Completed |
NCT01346384 -
Time - Related Cuff Pressure and Volume of the Laryngeal Tube With the Use of Nitrous Oxide
|
N/A | |
Completed |
NCT03535441 -
HMGB1 Release From Hemorrhagic Shock Patients
|
||
Completed |
NCT04819035 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - Indiana University Hospital
|
||
Completed |
NCT04958499 -
Effectiveness of Bio-Healthy Park on Adult
|
N/A | |
Recruiting |
NCT06007092 -
Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT04353388 -
Sepsis Post Market Observational Study and Potential Reduction of Time to Antibiotics - Washington University
|
||
Terminated |
NCT04276714 -
Revofitâ„¢ System Evaluation on Residual Limb Pain in Amputee Patients
|
N/A | |
Terminated |
NCT05641324 -
A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)
|
Phase 1 | |
Recruiting |
NCT05578872 -
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
|
Phase 1/Phase 2 | |
Suspended |
NCT03172897 -
Low-dose Dexmedetomidine in Mechanically Ventilated ICU Patients
|
Phase 4 |